Latest News

OncoSil Medical appoints as chief financial officer March 18, 2025

OncoSil Medical (ASX:OSL) has announced the appointment of Shelley Steyn as chief financial officer, effective 5 May.

Nyrada commences recruitment for phase one clinical trial March 18, 2025

Nyrada (ASX:NYR) has commenced recruitment for its phase one clinical trial of its lead drug candidate NYR-BI03.

Neurizon Therapeutics updates investors on initiatives to lift clinical hold March 18, 2025

Neurizon Therapeutics (ASX:NUZ) has updated investors on its ongoing engagement with the US FDA on lifting the clinical hold on the company's investigational new drug application for NUZ-001.

Race secures ethics approval for RC220 Phase 1 solid tumour trial March 18, 2025

Race Oncology (ASX:RAC) has announced that Bellberry has approved a phase one clinical trial of RC220 bisantrene alone and combined with doxorubicin in patients with solid tumours.

Radiopharm Theranostics says new data confirms positive tumour uptake March 18, 2025

Australian clinical-stage biopharmaceutical company Radiopharm Theranostics (ASX:RAD) has announced a poster presentation at the European Molecular Imaging Meeting.

Telix completes the acquisition of FAP-targeting theranostic candidates March 13, 2025

Telix Pharmaceuticals (ASX:TLX) has completed the transaction to expand its theranostic pipeline with new candidates targeting Fibroblast Activation Protein (FAP), one of the most promising pan-cancer targets in nuclear medicine.

Argent BioPharma signs exclusive agreement for Malta manufacturing facility March 13, 2025

Argent BioPharma (ASX:RGT) has signed an agreement with Dr Shlomo Sadoun granting him exclusive rights to facilitate a commercial transaction for the company's Malta-based GMP-certified manufacturing facility.

Proteomics International launches predictive test for diabetic kidney disease in Australia March 13, 2025

Proteomics International Laboratories (ASX:PIQ) has officially launched its first-in-class predictive test for diabetic kidney disease, PromarkerD, in Australia.

Noxopharm confirms the location of phase 1 HERACLES clinical trial March 13, 2025

Australian biotechnology company Noxopharm (ASX:NOX) has engaged Doherty Clinical Trials to conduct its upcoming phase 1 HERACLES trial.

Prescient Therapeutics announces appointment of new board chair March 11, 2025

Clinical-stage oncology company Prescient Therapeutics (ASX:PTX) has announced that Dr James Campbell will succeed Steven Engle as its chair.

4DMedical secures contract extension with the Cleveland Clinic March 11, 2025

Respiratory imaging technology company 4DMedical (ASX:4DX) has announced the renewal and extension of the contract for its pulmonary function software-as-a-service analysis with the Cleveland Clinic.

PolyNovo announces chief executive change March 11, 2025

PolyNovo (ASX:PNV) has announced that its chief executive officer, Swami Raote, will officially leave the company in June but will step down immediately.

Most Read

Radiopharm Theranostics says new data confirms positive tumour uptake

Neurizon Therapeutics updates investors on initiatives to lift clinical hold

OncoSil Medical appoints as chief financial officer

Race secures ethics approval for RC220 Phase 1 solid tumour trial

Nyrada commences recruitment for phase one clinical trial

New Stories

OncoSil Medical appoints as chief financial officer

Nyrada commences recruitment for phase one clinical trial

Neurizon Therapeutics updates investors on initiatives to lift clinical hold

Race secures ethics approval for RC220 Phase 1 solid tumour trial

Radiopharm Theranostics says new data confirms positive tumour uptake

Telix completes the acquisition of FAP-targeting theranostic candidates

Argent BioPharma signs exclusive agreement for Malta manufacturing facility

Sign In

Most Read

Radiopharm Theranostics says new data confirms positive tumour uptake

Neurizon Therapeutics updates investors on initiatives to lift clinical hold

OncoSil Medical appoints as chief financial officer

Race secures ethics approval for RC220 Phase 1 solid tumour trial

Nyrada commences recruitment for phase one clinical trial

Follow Us

New Stories

OncoSil Medical appoints as chief financial officer

Nyrada commences recruitment for phase one clinical trial

Neurizon Therapeutics updates investors on initiatives to lift clinical hold

Race secures ethics approval for RC220 Phase 1 solid tumour trial

Radiopharm Theranostics says new data confirms positive tumour uptake

Telix completes the acquisition of FAP-targeting theranostic candidates

Argent BioPharma signs exclusive agreement for Malta manufacturing facility